A press release issued by Semler Scientific (SMLR) articulates its investment in SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD). The announcement points to SDx’s DISCERN™ and its role in the diagnosis of early-stage AD. “We believe this investment continues to distinguish the accuracy of …
Memory loss can be brought on by a number of treatable medical issues, including Lyme disease, vitamin deficiencies, thyroid issues, drug interactions and the various forms of dementia. Some of the conditions that are often mistaken for Alzheimer’s disease (AD) can easily be addressed with inexpensive interventions. Without a definitive diagnosis, however, it’s frustrating, expensive and overwhelming for patients and families, providers and payers to know how to proceed in the care journey. To demonstrate how a definite diagnosis is now possible, SYNAPS Dx has released a short video that illustrates in simple terms …
Input your search keywords and press Enter.
Recent Comments